Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
NEW YORK, May 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) securities between August 13, 2014 and March 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
